The latest revision of the Declaration of Helsinki weakens protections for trial participants in low and middle income countries. Rafael Dal-Ré and colleagues argue that this is a step in the wrong direction
No takes yet. Share an insight, caveat, or question.
Dal‐Ré et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: